Design of the Dutch prevention of influenza, surveillance and management (PRISMA) studyHak, E., van Loon, S., Buskens, E., van Essen, G. A., de Bakker, D., Tacken, M. A. J. B., van Hout, B. A., Grobbee, D. E. & Verheij, T. J. M., 2-Apr-2003, In : Vaccine. 21, 15, p. 1719-1724 6 p.
Research output: Contribution to journal › Article › Academic › peer-review
Rationale and design of a study on the cost-effectiveness of the Dutch influenza vaccination campaign are described. During two influenza epidemics, about 75,000 primary care patients recommended for influenza vaccination are included. Cases have fatal or non-fatal influenza, pneumonia, otitis media, acute respiratory disease (ARD), heart failure, myocardial infarction, depression or diabetes dysregulation. Per case four controls are sampled, frequency matched on age and high-risk co-morbidity (<18 years, 18-64, >/=65 healthy, >/=65 with co-morbidity). Baseline and outcome data are retrieved from patient records. During the 1999-2000 influenza A epidemic 5891 (7.9%) high-risk children, 24,848 (33.2%) high-risk adults aged 18-64 years, 18,484 (24.7%) elderly with co-morbidity and 25,527 (34.1%) healthy elderly had been included. The mortality rate was 5.2 per 1000 and 2035 non-fatal outcome events were recorded (incidence rate 27.2/1000).
|Number of pages||6|
|Publication status||Published - 2-Apr-2003|
- Adolescent, Adult, Aged, Case-Control Studies, Child, Child, Preschool, Confidence Intervals, Cost-Benefit Analysis, Humans, Immunization Programs, Infant, Infant, Newborn, Influenza Vaccines, Influenza, Human, Logistic Models, Middle Aged, Netherlands, Odds Ratio, Population Surveillance